Androgen deprivation therapy with chemotherapy or abiraterone for patients with metastatic hormone-naive prostate cancer: a systematic review and meta-analysis. Review uri icon

Overview

abstract

  • Patients with metastasis prostate cancer underwent androgen deprivation therapy (ADT) in the considering of the leading role of androgen receptor pathway. However, the resistance occurred within 1 year or more. The combination of cytotoxic chemotherapy and abiraterone for ADT therapy was performed in recent randomized controlled trials. The meta-analysis was focused on the treatment comparisons between additional treatment with ADT and ADT alone. A significant difference was observed that the overall survival benefit of early and active additional treatment with ADT in patients with hormone-sensitive metastatic prostate cancer. However, a great proportion of patients with metastatic disease have metastases after receiving ADT. It will be important to further improve the treatment options.

publication date

  • February 11, 2019

Research

keywords

  • Androgen Antagonists
  • Androstenes
  • Antineoplastic Combined Chemotherapy Protocols
  • Prostatic Neoplasms, Castration-Resistant

Identity

Scopus Document Identifier

  • 85064214153

Digital Object Identifier (DOI)

  • 10.2217/fon-2018-0619

PubMed ID

  • 30741558

Additional Document Info

volume

  • 15

issue

  • 10